AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
Previous Symbol
CUSIPN/A
Phone617-914-8420
Debt
Debt-to-Equity RatioN/A
Current Ratio16.21
Quick Ratio16.21
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees34
Outstanding Shares23,940,000
Market Cap$656.83 million
OptionableN/A
Avrobio (NASDAQ:AVRO) Frequently Asked Questions
What is Avrobio's stock symbol?
Avrobio trades on the NASDAQ under the ticker symbol "AVRO."
How were Avrobio's earnings last quarter?
Avrobio Inc (NASDAQ:AVRO) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $2.51. View Avrobio's Earnings History.
When is Avrobio's next earnings date?
What price target have analysts set for AVRO?
6 brokerages have issued 12-month price targets for Avrobio's stock. Their forecasts range from $38.00 to $40.00. On average, they anticipate Avrobio's stock price to reach $39.50 in the next year. This suggests a possible upside of 37.0% from the stock's current price. View Analyst Price Targets for Avrobio.
What is the consensus analysts' recommendation for Avrobio?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.
Who are some of Avrobio's key competitors?
Some companies that are related to Avrobio include argenx (ARGX), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Regenxbio (RGNX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Rubius Therapeutics (RUBY), Editas Medicine (EDIT), Solid Biosciences (SLDB) and Autolus Therapeutics (AUTL).
Who are Avrobio's key executives?
Avrobio's management team includes the folowing people:
- Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 52)
- Ms. Katina Dorton, Chief Financial Officer (Age 60)
- Dr. Nerissa Kreher, Chief Medical Officer (Age 45)
- Mr. Jeffrey Medin Ph.D., Scientific Founder
- Dr. Kim Warren, Head of Operations
When did Avrobio IPO?
(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.
When does Avrobio's lock-up period expire?
Avrobio's lock-up period expires on Tuesday, December 18th. Avrobio had issued 5,247,958 shares in its initial public offering on June 21st. The total size of the offering was $99,711,202 based on an initial share price of $19.00. After the end of Avrobio's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Who are Avrobio's major shareholders?
Avrobio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.17%).
Which major investors are buying Avrobio stock?
AVRO stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC.
How do I buy shares of Avrobio?
Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avrobio's stock price today?
One share of AVRO stock can currently be purchased for approximately $28.83.
How big of a company is Avrobio?
Avrobio has a market capitalization of $656.83 million. Avrobio employs 34 workers across the globe.
What is Avrobio's official website?
How can I contact Avrobio?
Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]
MarketBeat Community Rating for Avrobio (NASDAQ AVRO)
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
